Welcome to our dedicated page for Verve Therapeutics news (Ticker: VERV), a resource for investors and traders seeking the latest updates and insights on Verve Therapeutics stock.
Verve Therapeutics was a clinical-stage company developing genetic medicines for cardiovascular disease before its completed acquisition by Eli Lilly and Company. Its public updates centered on in vivo base-editing programs such as VERVE-102, which targets PCSK9 in the liver to reduce LDL-C, along with clinical and regulatory disclosures, operating and financial results, and equity award activity under Nasdaq inducement-grant rules.
Company news also included investor-conference participation, material-agreement and shareholder-voting developments, governance matters, capital-structure disclosure, and risk-factor updates tied to its public-company status and acquisition process.
Eli Lilly (NYSE:LLY) has successfully completed its acquisition of Verve Therapeutics (NASDAQ:VERV), a Boston-based clinical-stage biotechnology company specializing in genetic medicines for cardiovascular disease. The strategic acquisition aims to revolutionize cardiovascular treatment through the development of one-time genetic therapies that could provide lifelong cardiovascular risk reduction.
Led by Ruth Gimeno, Lilly's group vice president of Diabetes and Metabolic Research and Development, this acquisition represents a significant step towards expanding Lilly's presence in the cardiovascular therapeutic space and advancing innovative genetic medicine solutions.
Eli Lilly (NYSE: LLY) has successfully completed its tender offer for Verve Therapeutics (NASDAQ: VERV). The offer, which expired on July 23, 2025, consisted of $10.50 per share in cash plus one non-tradable contingent value right (CVR) worth up to $3.00 per share upon achieving specific milestones.
The tender offer saw 49,882,464 shares validly tendered, representing approximately 55.7% of Verve's outstanding shares. All conditions of the offer have been met, and Lilly will promptly pay for all validly tendered shares. The acquisition is expected to be finalized on July 25, 2025.
Verve Therapeutics (VERV), a clinical-stage company focused on genetic medicines for cardiovascular disease, has announced its participation in two major investor conferences in June 2025. The company's management will engage in fireside chats at the Jefferies Global Healthcare Conference on June 4 at 9:20 a.m. ET in New York, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9 at 11:20 a.m. ET in Miami. Both events will be available via webcast on the company's website and archived for 30 days.
Verve Therapeutics (VERV), a clinical-stage biotech company focused on genetic medicines for cardiovascular disease, has granted equity awards to seven new employees under its 2024 Inducement Stock Incentive Plan. The grants include:
- Stock options for 134,860 shares at $5.67 per share, vesting over 4 years with 25% after year one and monthly thereafter
- 65,398 restricted stock units (RSUs) vesting equally over three years starting July 1, 2025
These grants were made as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).
Verve Therapeutics has announced positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102, a single-dose base editing treatment targeting PCSK9 for cardiovascular disease. The trial included 14 participants with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD).
Key findings across three dose cohorts (0.3, 0.45, and 0.6 mg/kg) showed:
- Mean LDL-C reduction of 53% and maximum reduction of 69% in the 0.6 mg/kg cohort
- Dose-dependent decreases in blood PCSK9 protein levels
- No treatment-related serious adverse events
- No clinically significant changes in ALT or platelets
The company plans to announce final dose escalation data in H2 2025, initiate Phase 2 trials, and receive Eli Lilly's decision on their PCSK9 program opt-in. Current funding is expected to last until mid-2027.
Verve Therapeutics has received FDA Fast Track designation for VERVE-102, an investigational base editing medicine targeting PCSK9 for treating hyperlipidemia patients with high cardiovascular risk. VERVE-102 is designed as a single-course treatment to permanently deactivate the PCSK9 gene in the liver and reduce LDL-C levels.
The treatment is currently in Phase 1b Heart-2 clinical trial, evaluating safety and tolerability in patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD). The company plans to announce initial safety and efficacy data from the first three dose cohorts (0.3, 0.45, and 0.6 mg/kg) in Q2 2025.
The Fast Track status may enable more frequent FDA communications and potential Priority Review. Verve plans to report final dose escalation data, deliver the opt-in package to Eli Lilly, and begin Phase 2 trials in H2 2025.
Verve Therapeutics, a clinical-stage cardiovascular genetic medicine company, has announced new equity awards granted to three employees on March 31, 2025. The inducement grants, made under the company's 2024 Inducement Stock Incentive Plan, include:
- Stock options to purchase 50,700 shares at $4.57 per share (closing price on grant date)
- 17,800 restricted stock units (RSUs)
The stock options have a 10-year term with a four-year vesting schedule: 25% vesting after one year, followed by monthly installments over three years. The RSUs will vest equally over three years, starting April 1, 2025. Both grants require continued employment for vesting.